International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 16s,2025
https://theaspd.com/index.php

Reprogramming The Endocannabinoid System With Emerging Therapeutic Targets For Smart Analgesia - A Comprehensive Review

Butchi Raju Akondi[1], Siva Reddy Challa[2], Mallamma T[3], Jashwanth H D[4], Parameshwari P[5], Sara S[6]
[1]Assistant Professor, Department of Clinical Pharmacy and Pharmacology, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia.
[2]Research Assistant Professor, Department of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Illini Dr, Peoria-61605, Illinois, USA & Professor, Department of Pharmacology, KVSR Siddhantha College of Pharmaceutical Sciences, Siddhantha Nagar, Vijayawada, India 520010.
[3]Department of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagara – 571448, Karnataka, India.
[4]Department of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagara – 571448, Karnataka, India.
[5]Professor & HOD, Department of Community Medicine, Government Villupuram Medical College, Villupuram, Tamil Nadu, India.
[6]Department of Internal Medicine, A. R. Hospitals, Ramanathapuram, Tamil Nadu, India

Abstract
Neuropathic pain, a relentless and elusive clinical adversary, continues to defy the efficacy of traditional analgesics. Amid this therapeutic impasse, the endocannabinoid system (ECS) emerges as a dynamic neuroimmune symphony conductor in modulating pain signalling with intricate precision. This review ventures into the molecular corridors of the ECS, spotlighting CB1 and CB2 receptors, FAAH, MAGL, anandamide uptake systems, and sigma-1 receptors as molecular sentinels guarding the gateways of nociception. Among them, CB2 receptor activation and FAAH inhibition unveil a compelling, non-euphoric route to pain suppression, offering analgesia untethered from the psychoactive shadow of CB1. Furthermore, hybrid strategies involving imidazoline I2 receptors and voltage-gated ion channels form a pharmacological mosaic that synergistically silences aberrant pain pathways. With a blend of receptor finesse and enzymatic modulation, the ECS paves a novel therapeutic frontier, one where chronic pain is not merely managed but molecularly outmanoeuvred.
Keywords: *Neuropathic pain, Endocannabinoid System, Analgesia, Therapeutic Targets, Pain Management*

1.0 Cannabinoid Receptors in the Landscape of Neuropathic Pain Mechanisms

The endocannabinoid system (ECS), though historically associated with psychotropic modulation, is now emerging as a multidimensional regulatory architecture with profound implications for neuropathic pain. Central to this system are two distinct receptor classes,CB1 and CB2 each exhibiting a differential expression blueprint that mirrors their divergent physiological roles. CB1 receptors, predominantly embedded within neuronal populations across central and peripheral circuits, manifest as key modulators of nociceptive transmission (Tsou et al., 1998; Hohmann et al., 1999; Farquhar-Smith et al., 2000; Salio et al., 2002b). Their coupling with Gi/o proteins facilitates downstream inhibition of adenylyl cyclase, establishing a suppressive synaptic tone (Howlett et al., 1986). CB2 receptors, on the other hand, were initially relegated to immunological terrains due to their preferential expression on immune effector cells (Munro et al., 1993; Facci et al., 1995), but subsequent discoveries have redefined their neuroplastic potential under pathological conditions. Within the dorsal root ganglia (DRG), CB1 receptor expression is not uniform but instead follows a nuanced topography enriched in medium- to large-caliber neurons (Bridges et al., 2003), with a parallel pattern discernible in the trigeminal ganglia (Price et al., 2003). Notably, this expression is not static; inflammatory cues and neural trauma dynamically reshape CB1 expression landscapes, particularly enhancing their presence in C-fiber nociceptors and post-lesional DRG compartments (Amaya et al., 2006; Walczak et al., 2005; Mitrirattanakul et al., 2006). The functional asymmetry extends into the spinal cord, where CB1 receptors localize predominantly to non-TRPV1 afferents and astrocytic subpopulations in the dorsal horn's laminae I and II (Salio et al., 2002a), with injury-induced upregulation confined to the ipsilateral nociceptive fields (Lim et al., 2003; Walczak et al., 2005).In contrast, CB2 receptor activity in baseline conditions remains cryptic

within sensory neurons, suggesting a quiescent or latent functional role (Wotherspoon et al., 2005; Zhang et al., 2003). Yet, this receptor is not inert; nerve injury acts as a molecular switch, catalyzing CB2 transcriptional activity in both DRG and spinal territories (Zhang et al., 2003; Wotherspoon et al., 2005; Beltramo et al., 2006). The various molecular targets summary were shown in table 1.The specificity of this response to neurotrauma, rather than inflammation per se, intimates a distinct immune-neuro interface where CB2 might orchestrate neuroimmune recalibration. Notably, models such as spinal or saphenous nerve ligation further substantiate this context-dependent CB2 mobilization, marking it as a compelling target for precision analgesics (Walczak et al., 2005, 2006).

2.0 Targeting CB2 Receptors: A Promising Pathway in Cannabis-Based Neuropathic Pain Therapy

The enduring human relationship with cannabis for therapeutic use has evolved significantly with scientific validation of its pharmacologically active constituents. Among these, Δ9-tetrahydrocannabinol (THC) has emerged as a central player, demonstrating affinity for cannabinoid receptors CB1 and CB2, both G protein-coupled receptors implicated in numerous physiological processes (Pertwee, 2005). While CB1 receptors predominantly mediate psychoactive effects due to their localization in the central nervous system, the CB2 receptors have attracted growing interest due to their minimal central expression and pronounced role in immune cell modulation. This delineation provides a compelling rationale for the investigation of CB2 as a target in neuropathic pain, circumventing the psychoactive drawbacks associated with CB1 activation.Therapeutic cannabinoids such as Sativex TM, a standardized cannabis extract, have validated clinical applications for multiple sclerosis-related pain (Perezm et al., 2008; Ashton et al., 2007). However, psychoactivity and dependence concerns rooted in CB1 engagement constrain broader application. Conversely, emerging data underscore CB2 receptor expression in brain-resident microglia under pathological states, directly linking CB2 to central sensitization mechanisms pivotal to chronic pain syndromes (Atwood et al., 2010; Latremoliere et al., 2009). Notably, CB2-selective agonists like HU-308 and AM1241 have demonstrated potent anti-nociceptive and anti-hyperalgesic effects in preclinical models, effects abrogated by CB2 antagonists but not CB1 antagonists, reinforcing a CB2-centric mechanism of action (Hanus et al., 1999; LaBuda et al., 2005; Malan et al., 2001; Nackley et al., 2003). Intriguingly, AM1241 has shown self-administration behavior in neuropathic rats, suggesting intrinsic analgesic-seeking behavior without reinforcing abuse potential (Gutierrez et al., 2011). Complementary findings with GW405883 further highlight CB2 activation as a promising avenue for analgesia devoid of central side effects (Valenzano et al., 2005).Parallel to receptor targeting, enzymatic modulation of the endocannabinoid system presents another frontier, notably via fatty acid amide hydrolase (FAAH), which hydrolyzes anandamide (AEA), an endogenous CB receptor ligand. FAAH knockout models exhibit elevated AEA and attenuated pain sensitivity, pointing to FAAH as a key regulator of nociception (Cravatt et al., 2001; Lichtman et al., 2004). Interestingly, FAAH activity appears susceptible to modulation by oxidative byproducts like hydroperoxides from lipoxygenase (LOX), suggesting interplay between inflammatory mediators and endocannabinoid tone (Maccarrone et al., 2000b; Phillis et al., 2006). Region-specific FAAH deletions have further distinguished the peripheral enzyme's dominant role in inflammatory pain over central modulation (Cravatt et al., 2004b).Pharmacological FAAH inhibitors such as URB597 and OL135 have recapitulated genetic findings, eliciting analgesia in models of inflammatory pain, though outcomes in neuropathic pain models remain inconsistent (Jayamanne et al., 2006; Chang et al., 2006; Russo et al., 2007). These disparities may reflect differential endocannabinoid dynamics and receptor engagement under chronic neuropathic states. For instance, URB597's dose-dependent elevation of AEA and 2AG did not linearly translate into analgesia; paradoxically, higher doses triggered transient hyperalgesia, underscoring complex dose-response relationships (Richardson et al., 2007; Robinson et al., 2006). Furthermore, CNS-sparing FAAH deletions and region-specific drug delivery reveal that peripheral FAAH inhibition necessitates higher concentrations to impact central nociceptive circuits, especially in neuropathic contexts (Jhaveri et al., 2006). Compounds like N-arachidonoyl-serotonin, combining FAAH inhibition with TRPV1 antagonism, offer multimodal analgesia, emphasizing the therapeutic promise of hybrid pharmacological strategies (Maione et al., 2007).Together, the CB2 receptor and FAAH enzyme represent two pivotal, yet mechanistically distinct, targets within the endocannabinoid system. Their modulation offers nuanced control over pain pathways with potential for reduced side effect profiles compared to conventional analgesics. Strategic targeting of these components whether via selective receptor agonists or enzyme inhibitors could redefine therapeutic approaches

to chronic and neuropathic pain. Expression and localization of CB1 and CB2 receptors in normal and neuropathic conditionse shown in Fig 1.

Table 1: Comparative Summary of Molecular Targets in Neuropathic Pain

Target Class	Specific Receptor/ Enzyme	Expression Sites	Endogenous Ligands	Notable Ligands (Antagonists/ Agonists)	Preclinical Efficacy	Clinical Trial Status	Reference
Endocannabinoid	CB2	Immune cells, CNS	2-AG, AEA	JWH-133, AM1241	Anti-hyperalgesia	Phase II (CB2 agonists)	(Nazemi et al. 2025)
Endocannabinoid	FAAH	CNS, liver, kidney	AEA	URB597, PF-04457845	Reduced allodynia	Phase I/II	(Schlosburg, Kinsey, and Lichtman 2009a)
Endocannabinoid	MAGL	CNS, PNS	2-AG	JZL184, MJN110	Delayed pain onset	Preclinical	(Zhang et al. 2024)
Sigma	Sigma-1	DRG, spinal cord, brain	Unknown (chaperone role)	PRE-084, BD1063	Anti-nociceptive	Ongoing Phase II	(Wu et al. 2020)
Imidazoline	I2	Brainstem, DRG	Agmatine	2-BFI, CR4056	Synergistic with opioids	Phase II (CR4056)	(Baderkhan et al. 2018)
Histamine	H4	Immune cells, DRG	Histamine	JNJ7777120, VUF6002	Anti-inflammatory	Early Preclinical	(Gerig 2011)
Purinergic	P2X3	DRG, vagus nerve	ATP	Gefapixant	Reduced cough/pain	FDA-approved (Gefapixant)	(Iacobucci 2017)



Figure 1: Expression and localization of CB1 and CB2 receptors in normal and neuropathic conditions across dorsal root ganglia (DRG) and spinal cord.

3.0 FAAH Inhibitors in Pain Management: Complexities and Hybrid Therapeutic Strategies

Pharmacological FAAH inhibitors such as URB597 and OL135 have recapitulated genetic findings, eliciting analgesia in models of inflammatory pain, though outcomes in neuropathic pain models remain inconsistent (Jayamanne et al., 2006; Chang et al., 2006; Russo et al., 2007). These disparities may reflect differential endocannabinoid dynamics and receptor engagement under chronic neuropathic states. For instance, URB597's dose-dependent elevation of AEA and 2AG did not linearly translate into analgesia; paradoxically, higher doses triggered transient hyperalgesia, underscoring complex dose-response relationships (Richardson et al., 2007; Robinson et al., 2006). Furthermore, CNS-sparing FAAH deletions and region-specific drug delivery reveal that peripheral FAAH inhibition necessitates higher concentrations to impact central nociceptive circuits, especially in neuropathic contexts (Jhaveri et al., 2006). Compounds like N-arachidonoyl-serotonin, combining FAAH inhibition with TRPV1 antagonism, offer multimodal analgesia, emphasizing the therapeutic promise of hybrid pharmacological strategies (Maione et al., 2007).In addition to FAAH, monoacylglycerol lipase (MAGL) has emerged as a vital enzyme orchestrating the breakdown of the endocannabinoid 2-arachidonoylglycerol (2AG), especially within central neural territories (Dinh et al., 2002). Although FAAH's partial involvement in 2AG metabolism has been recognized (Cravatt et al., 1996; Bisogno et al., 1997; Goparaju et al., 1998, 1999; Ueda et al., 1998; Lang et al., 1999; Fowler et al., 2001; Ueda, 2002), the scarcity of potent and selective MAGL inhibitors has historically limited functional insights. URB602, despite being proposed as a MAGL-specific agent, demonstrates limited efficacy and controversial specificity, as subsequent analyses revealed concurrent FAAH inhibition (Muccioli et al., 2007; Vandevoorde et al., 2007). Nevertheless, targeted administration of URB602 has shown to elevate 2AG levels in discrete brain regions and mitigate nociception in inflammatory models via CB2-dependent pathways (Hohmann et al., 2005; Guindon et al., 2007), suggesting that selective MAGL inhibition may offer a novel analgesic strategy once more refined pharmacological tools are developed.Beyond catabolic pathways, the regulation of endocannabinoid bioavailability through cellular uptake mechanisms presents another dimension in analgesic research. Although the molecular identity of the anandamide (AEA) transporter remains elusive (Glaser et al., 2003, 2005), a suite of putative transport inhibitors, including AM404, UCM707, and OMDM analogs, has been explored for their modulatory potential. UCM707, despite limited interaction with CB1 and TRPV1, does bind to CB2 receptors (Lopez-Rodriguez et al., 2003), complicating interpretations of its pharmacodynamics. These uptake inhibitors generally exhibit moderate antinociceptive effects compared to FAAH inhibitors; however, synergistic actions have been noted when paired with exogenous AEA or in pathological pain states. AM404, notable for its multimodal action on TRPV1, CB receptors, and FAAH (Jarrahian et al., 2000; Rawls et al., 2006), alleviates hyperalgesia in neuropathic and inflammatory models, effects that are reversed by a triad of CB1, CB2, and TRPV1 antagonists (Costa et al., 2006). Additionally, its COX-inhibitory properties (Hogestatt et al., 2005) suggest a broader anti-inflammatory spectrum. Among newer compounds, OMDM-2 has demonstrated superior endocannabinoid-elevating capability relative to UCM707, though its precise analgesic profile remains to be fully elucidated (Ortar et al., 2003; de Lago et al., 2005).Sigma-1 receptors (S1Rs), initially characterized as enigmatic pharmacological entities, have emerged as critical neuromodulatory elements implicated in nociceptive signaling. Encoded by a gene with no homology to traditional mammalian proteins, the S1R is a 223-amino acid protein predominantly localized to the endoplasmic reticulum but capable of dynamic redistribution to the plasma membrane under certain conditions (Hanner et al., 1996; Pan et al., 1998; Prasad et al., 1998). Functionally, S1Rs act as molecular chaperones, regulating intracellular calcium fluxes through IP3 receptor modulation and influencing the trafficking of lipids and signaling complexes (Hayashi et al., 2000; Hayashi et al., 2001; Hayashi et al., 2003, 2005). S1Rs modulate key receptors and ion channels including NMDA, dopamine, GABA, and potassium/calcium channels, thereby exerting control over diverse cellular processes (Aydar et al., 2002; Martina et al., 2007; Monnet et al., 1990).

Experimental models have delineated a pronounced role for S1Rs in the modulation of neuropathic pain. S1R agonists antagonize opioid-induced analgesia, while S1R antagonists and gene silencing techniques enhance opioid efficacy, suggesting a modulatory influence on antinociceptive pathways (Chien et al., 1994, 1995; Mei et al., 2002). Notably, S1R-deficient mice display marked resistance to nerve injury-induced mechanical and cold allodynia but retain normal sensitivity to acute nociceptive stimuli, indicating a selective role in central sensitization mechanisms (Cendán et al., 2005a, 2005b; Kim et al., 2006; Roh et al., 2008). Intrathecal administration of S1R antagonists attenuates nociceptive behavior and suppresses spinal ERK and NMDA

receptor signaling, underscoring the receptor's involvement in activity-dependent sensitization (Kim et al., 2006; Roh et al., 2008a, 2008b).

Furthermore, S1Rs are strategically positioned within superficial dorsal horn laminae, sites crucial for nociceptive processing, and exhibit dynamic upregulation post-injury. Their influence on wind-up phenomena—enhanced neuronal responses to repetitive stimuli parallels their established role in hippocampal plasticity (Martina et al., 2007). Through interactions with NMDA and NK1 receptors, and modulation of calcium-dependent signaling cascades including PLC, IP3, PKC, and ERK pathways, S1Rs orchestrate prolonged sensitization responses (Ji et al., 1999; Kawasaki et al., 2004; Xin et al., 2006; Zhuang et al., 2005). Pharmacological inhibition of ERK signaling in S1R-deficient models further corroborates their central role in perpetuating neuropathic pain phenotypes. Together, these data support the proposition of S1Rs as integral components of spinal pain circuitry and potent therapeutic targets for neuropathic pain relief.

Collectively, CB2 receptors, FAAH, MAGL, AEA transport mechanisms, and S1Rs delineate a complex, interdependent regulatory network modulating endocannabinoid and neuroplastic pathways in nociceptive processing were presented in Table 2. Each component presents a unique intervention point for the development of innovative, side-effect-sparing analgesics aimed at disrupting the maladaptive sensitization underlying chronic and neuropathic pain conditions.

Table 2: Mechanistic Overview of FAAH, MAGL, and AEA Uptake with Synergistic Pathways

Target	Function	Substrates	Inhibitors	Pain Model Used	Outcome	Synergistic Pathway	Reference
FAAH	Hydrolyzes AEA	AEA, OEA	URB597, PF-3845	Neuropathic (CCI, SNI)	↓ Mechanical allodynia	FAAH inhibition ↑AEA → CB1/CB2 activation + ↓ TRPV1 activation	(Schlosburg, Kinsey, and Lichtman 2009b)
MAGL	Hydrolyzes 2-AG	2-AG	JZL184	CCI, diabetic neuropathy	↑ 2-AG, ↓ pain behaviors	MAGL inhibition ↑2-AG → CB1/CB2 activation + suppression of proinflammatory prostaglandins	(Rodriguez-Diaz et al. 2011)
AEA Uptake	Membrane transporter (unspecified)	AEA	VDM11, AM404	SNL, paclitaxel models	↑ Endocannabinoid tone	AEA uptake blockade synergizes with FAAH inhibition to enhance CB1/CB2 signaling	(Sakamoto et al. 2007)



Figure 2: Sigma-1 receptor expression and involvement in central sensitization pathways related to neuropathic pain.

4.0 Sigma-1 Receptors: Key Modulators of Neuropathic Pain and Central Sensitization

Experimental models have delineated a pronounced role for S1Rs in the modulation of neuropathic pain. S1R agonists antagonize opioid-induced analgesia, while S1R antagonists and gene silencing techniques enhance opioid efficacy, suggesting a modulatory influence on antinociceptive pathways (Chien et al., 1994, 1995; Mei et al., 2002). Notably, S1R-deficient mice display marked resistance to nerve injury-induced mechanical and cold allodynia but retain normal sensitivity to acute nociceptive stimuli, indicating a selective role in central sensitization mechanisms (Cendán et al., 2005a, 2005b; Kim et al., 2006; Roh et al., 2008). Intrathecal administration of S1R antagonists attenuates nociceptive behavior and suppresses spinal ERK and NMDA receptor signaling, underscoring the receptor's involvement in activity-dependent sensitization (Kim et al., 2006; Roh et al., 2008a, 2008b). Sigma-1 receptor expression was shown in Fig 2.

Furthermore, S1Rs are strategically positioned within superficial dorsal horn laminae, sites crucial for nociceptive processing, and exhibit dynamic upregulation post-injury. Their influence on wind-up phenomena—enhanced neuronal responses to repetitive stimuli—parallels their established role in hippocampal plasticity (Martina et al., 2007). Through interactions with NMDA and NK1 receptors, and modulation of calcium-dependent signaling cascades including PLC, IP3, PKC, and ERK pathways, S1Rs orchestrate prolonged sensitization responses (Ji et al., 1999; Kawasaki et al., 2004; Xin et al., 2006; Zhuang et al., 2005). Pharmacological inhibition of ERK signaling in S1R-deficient models further corroborates their central role in perpetuating neuropathic pain phenotypes. Together, these data support the proposition of S1Rs as integral components of spinal pain circuitry and potent therapeutic targets for neuropathic pain relief.Imidazoline receptors, long recognized for their role in cardiovascular regulation, have garnered renewed attention for their neuromodulatory functions in pain signaling. These receptors, categorized into I1, I2, and I3 subtypes based on ligand-binding profiles, exhibit distinct physiological roles. I1 receptors, predominantly implicated in the central regulation of blood pressure, are targeted by antihypertensives like rilmenidine and moxonidine, whose ancillary analgesic properties are primarily mediated through adrenergic α2 receptors rather than direct imidazoline interaction (Fairbanks et al., 2009; Armah et al., 1988). In contrast, the I2 receptor subtype, although not yet molecularly cloned, has emerged as a promising target in neuropathic pain due to its distinctive pharmacology and functional relevance (Diaz et al., 1997; Head et al., 2006).

Agmatine, an endogenous amine derived from arginine decarboxylation, epitomizes a multifunctional I2 ligand. Acting as a neuromodulator, agmatine interfaces with imidazoline and adrenergic receptors while also modulating NMDA receptor function and nitric oxide synthesis (Halaris and Plietz, 2007; Berkels et al., 2004). In neuropathic models, systemic and intrathecal administration of agmatine has shown robust efficacy in mitigating allodynia and hyperalgesia, reversing pain behaviors across various rodent paradigms, including sciatic nerve ligation and diabetic neuropathy (Fairbanks et al., 2000c; Karadag et al., 2003; Courteix et al., 2007). Despite its non-selectivity, the persistent antinociceptive outcomes point to the I2 receptor as a plausible mediator of agmatine's analgesic profile.imidazoline receptor sub types and its role were shown in fig 3.



Figure 3**: Roles of Imidazoline Receptor Subtypes (I_1, I_2, I_3) in Pain Modulation**.

While high-dose systemic agmatine raises concerns over pharmacodynamic specificity (Onal et al., 2003), spinal applications yield potent, long-lasting effects even at nanomolar concentrations, indicating a potential for reversing neuroplastic changes associated with chronic pain. Further validation comes from diabetic neuropathy models, where agmatine consistently attenuates thermal and mechanical hypersensitivity, underscoring its translational promise (Wuarin-Bierman et al., 1987; Ahlgren et al., 1993).

As imidazoline I2 receptor ligands display efficacy primarily in chronic, rather than acute pain models, they hold promise as adjuncts or alternatives to opioids. Importantly, they tend not to exacerbate opioid side effects and may even mitigate them, supporting their role in multimodal pain strategies. Future research should prioritize the development of selective, "silent" I2 ligands to conclusively delineate receptor-specific mechanisms, alongside exploration of structure-activity relationships that could lead to clinically viable agents with improved therapeutic indices.

Collectively, CB2 receptors, FAAH, MAGL, AEA transport mechanisms, S1Rs, and imidazoline receptors delineate a complex, interdependent regulatory network modulating endocannabinoid and neuroplastic pathways in nociceptive processing were shown in Table 3. Each component presents a unique intervention point for the development of innovative, side-effect-sparing analgesics aimed at disrupting the maladaptive sensitization underlying chronic and neuropathic pain conditions.

Table 3: Ligand-Receptor Binding Affinity and Synergistic Pathway Integration for Neuropathic Pain Targets

Target Receptor	Representative Ligand	Binding Affinity (Ki / IC_{50})	Functional Relevance in Neuropathic Pain	Clinical/ Experimental Status	Synergistic Pathways	Reference
CB2	JWH-133	Ki ≈ 3.4 nM	Anti-inflammatory, inhibits microglial activation	Preclinical to Phase II	CB2–P2X4 microglial axis	(Guindon and Hohmann 2008)
FAAH	MK-4409	IC_{50} ≈ 1.2 nM	Prevents AEA degradation, prolongs endocannabinoid analgesia	Preclinical	FAAH–TRPV1 desensitization loop	(Chobanian et al. 2014)

MAGL	JZL184	IC_{50} ≈ 8 nM	Elevates 2-AG levels, reduces pain hypersensitivity	Preclinical	MAGL–CB1–P2Y12 triad	Wikipedia: MAGL
AEA Uptake	AM404	IC_{50} ≈ 4 μM	Inhibits AEA reuptake, prolongs endocannabinoid effects	Experimental	AEA–sigma-1–TRPV1 interplay	(Placzek et al. 2008)
Sigma-1	PRE-084	Ki ≈ 44 nM	Modulates calcium signaling, suppresses neuropathic pain	Preclinical	Sigma-1–NMDA–BDNF pathway	(Shinu et al. 2022)
I2 (Imidazoline)	CR4056	Ki ≈ 20 nM	Attenuates neuropathic and inflammatory pain	Phase II	I2–monoamine–opioid synergy	(Lau and Vaughan 2014)
Agmatine	Endogenous	~0.5 μM	NMDA antagonist, promotes neuroprotection	Experimental	Agmatine–I2–NO synthase inhibition	(Reis and Regunathan 1998) D.J.
H4	JNJ7777120	IC_{50} ≈ 5.7 nM	Reduces mast cell activation and inflammation	Preclinical	H4–CB2–histamine feedback loop	(Bernatoniene et al. 2023)
P2X4	5-BDBD	IC_{50} ≈ 1 μM	Modulates spinal microglia in pain hypersensitivity	Preclinical	CB2–P2X4–BDNF cross-talk	(Sadhasivam et al. 2015)
P2Y12	PSB-0739	Ki ≈ 0.26 nM	Suppresses microglial reactivity and inflammation	Experimental	MAGL–P2Y12–neuroimmune loop	(Shinu et al. 2022)

5.0 NMDA Receptor Antagonists in Pain Management: Promise and Limitations

Ionotropic glutamate receptors, particularly the NMDA subtype, play a pivotal role in modulating nociceptive transmission and central sensitization. Pharmacological agents targeting these receptors, especially competitive antagonists like ketamine, dextromethorphan, amantadine, and memantine, have found varied clinical applications, primarily in pain management. Ketamine, a dissociative anesthetic, demonstrates substantial anti-inflammatory and analgesic potential at sub-anesthetic levels across diverse experimental paradigms, both human and animal [Fundytus et al., 2001]. Its adjunctive use diminishes opioid requirements and mitigates tolerance and psychological dependence in oncology settings [Sen et al., 2006; Mercadante et al., 2000; Akin et al., 2005]. Nonetheless, its long-term utility is curtailed by neuropsychiatric side effects such as hallucinations, cognitive dysfunction, and sedation [Fundytus et al., 2001]. Dextromethorphan, though less selective, exhibits promising anti-nociceptive properties in preclinical studies and clinical trials focused on diabe

Ionotropic neuropathy and post-herpetic neuralgia, albeit with inconsistent efficacy [Hao et al., 1996; Thisted et al., 2006]. It has shown benefit in treating phantom limb pain and pain post-traumatic brain injury, while remaining ineffective against other neuralgias [Ben et al., 2003; Carlsson et al., 2004; Gilron et al., 2000]. Its tolerability profile surpasses ketamine's [Carlsson et al., 2004]. Memantine, widely used for Alzheimer's, induces fewer NMDA-mediated side effects but lacks consistent analgesic efficacy across various neuropathic conditions [Parsons et al., 1999; Maier et al., 2003; Wiech et al., 2004; Schifitto et al., 2006]. Similarly, amantadine's adverse cardiovascular and neurological reactions limit its therapeutic index [Fukui et al., 2001]. Other antagonists such as dizocilpine and selfotel failed clinical trials due to toxicity concerns. Experimental agents like LY235959 and Agmatine continue to show promise in preclinical models [Davis et al., 2000; Fairbanks et al., 2000]. Ongoing trials for compounds like CHF3381, EAA090, CNS5161, and Compound 10 suggest the field remains dynamic [Villetti et al., 2003; Childers et al., 2002]. Role of Agmatine vs. I2 Ligands in Neuropathic Pain: Mechanistic and Behavioral Comparison were shown in Table 4.

Notably, selective antagonism of the NR2B subunit, which is regionally localized in pain-relevant CNS structures, offers a novel analgesic pathway. Agents like CP101606 and Ro25-6981 target this subunit with high specificity, demonstrating analgesia in multiple pain models with fewer cognitive side effects [Boyce et al., 1999; Nakazato et al., 2005; Taniguchi et al., 1997]. Despite CP101606's discontinuation in stroke trials, its safety profile in terms of learning and motor functions remains favorable. Ro25-6981 continues to show promise in mechanical hyperalgesia models [Boyce et al., 1999]. Vaccination strategies targeting NR2B peptides also show neurobehavioral improvement post-injury [Wang et al., 2007]. Other NR2B-selective candidates in development, such as RGH-896 and the EVT series, offer improved oral efficacy and tolerability. Meanwhile, modulation of the NR1 subunit's glycine B site represents a complementary strategy. Glycine B antagonists exhibit lower side effect burdens and superior pharmacokinetics [Wallace et al., 2002]. Although candidates like GV196771 and ACEA1021 yielded preclinical success, translation was hindered by bioavailability issues and metabolic limitations [Bordi et al., 2000; Quartaroli et al., 2000; Lutfy et al., 1998; Woodward et al., 1995]. New compounds, including MRZ2/576 and AV-101, continue to advance through early clinical phases [Zhu et al., 2006]. Subtype-specific targeting of NR2B has garnered significant attention due to its involvement in post-SCI neuropathic pain. Its localized expression in the dorsal horn of the spinal cord and forebrain makes it an ideal candidate for site-specific modulation [Boyce et al., 1999; Laube et al., 1998]. Selective NR2B blockade demonstrates efficacy in reducing hyperexcitability in spinal neurons post-SCI, as evidenced by electrophysiological recordings and behavioral assays [Eide et al., 2004; Hains et al., 2003]. Interestingly, intrathecal administration of ifenprodil and Ro25-6981 elevated mechanical thresholds in both hemisection and contusion SCI models, suggesting a spinal site of action [Qu et al., 2009]. Despite differential expression levels of NR2B protein and mRNA across models, the functional impact on pain modulation appears comparable, possibly due to post-translational regulation such as phosphorylation rather than absolute expression [Abe et al., 2005; Caudle et al., 2005]. Moreover, ifenprodil's interactions with serotonergic and adrenergic receptors may confer additional analgesic effects, particularly in models involving serotonergic dysregulation [Chenard et al., 1991; Hains et al., 2002]. These findings underscore the need for nuanced exploration of receptor dynamics, including downstream signaling and degradation pathways like the ubiquitin-proteasome system, to fully elucidate NR2B's therapeutic potential [Huh et al., 1996; Roh et al., 2011; Lee et al., 2007].

Table 4. Role of Agmatine vs. I2 Ligands in Neuropathic Pain: Mechanistic and Behavioral Comparison

Parameter	Agmatine	I2 Receptor Ligands (e.g., CR4056)	Comparative Insight	Reference
Receptor Specificity	Binds NMDA receptors, α2-adrenoceptors, and imidazoline receptors; inhibits nitric oxide synthase (NOS)	High affinity for imidazoline I2 binding sites; indirect modulation of monoaminergic systems	Agmatine shows broader receptor promiscuity, while I2 ligands are more selective	(Jouvet et al. 1995)
Primary Mechanisms	NMDA antagonism, inhibition of nitric oxide production, α2-adrenoceptor activation, anti-glutamatergic	Enhances monoamine neurotransmission (5-HT, NA), modulates pain via I2 receptor-mediated glial interaction	Agmatine works through neuroprotective and anti-excitotoxic routes; I2 ligands act primarily through monoaminergic modulation	(Korkotian et al. 2013) (Škugor, Krasnov, and Andersen 2014)
Neuroimmune Interactions	Inhibits iNOS, reduces pro-inflammatory cytokines; neuroprotective glial modulation	Reduces glial activation and neuroinflammation; downregulates pro-nociceptive cytokines	Both reduce glial-derived inflammation but via different upstream mechanisms	(Haferkamp and Rizos 2010)

Analgesic Effects in Animal Models	Effective in CCI, SNL, and diabetic neuropathy models	Demonstrated efficacy in CCI and SNL models; synergistic with opioids	Comparable efficacy; agmatine may outperform in nitric oxide-mediated neuropathies	(Nakamura et al. 2003) (Haferkamp and Rizos 2010)
Synergistic Pathways	Synergizes with morphine, gabapentin, and NO inhibitors	Potentiates opioid analgesia, reduces tolerance; interacts with monoaminergic drugs	Both enhance opioid efficacy but via non-overlapping mechanisms	(Gu, Wind, and Reines 1996)
Side Effect Profile	Low toxicity in preclinical models; potential hypotensive effects	Favorable preclinical profile; minimal CNS side effects at analgesic doses	Both well-tolerated; agmatine's broader receptor range may carry more off-target effects	(Korkotian et al. 2013) (Haferkamp and Rizos 2010)
Translational Potential	Phase I studies for neurodegenerative and pain disorders	CR4056 has reached Phase II for osteoarthritis and neuropathic pain	I2 ligands are further along in clinical development; agmatine remains promising but underexplored	(Haferkamp and Rizos 2010)

6.0 Voltage-Gated Sodium Channels: Key Drivers and Therapeutic Targets in Neuropathic Pain

Voltage-gated sodium channels (VGSCs) have emerged as pivotal molecular mediators in the pathophysiology of neuropathic pain, primarily due to their critical role in modulating neuronal excitability. Dorsal root ganglion (DRG) neurons, the primary afferents of the peripheral nervous system, express a broad repertoire of sodium channel isoforms—at least six out of nine identified variants [Black et al., 1996]. Although these neurons typically exhibit subdued electrical activity under homeostatic conditions, injury to peripheral nerves precipitates a marked shift toward hyperexcitability, engendering aberrant spontaneous discharges [Dickenson et al., 2002; Matzner et al., 1994; Liu et al., 2000; Waxman et al., 1999]. Central to this maladaptive electrophysiological state is the altered expression and distribution of VGSC isoforms, as observed in various experimental paradigms post-axonal trauma or inflammatory insult [Waxman et al., 1999; Cummins et al., 1997; Dib-Hajj et al., 1999; Black et al., 1999; Black et al., 2000; Sleeper et al., 2000]. However, ambiguity persists regarding whether therapeutic interventions should selectively target individual channel subtypes or adopt a more holistic approach addressing the broader isoform network.Nav1.3, a TTX-sensitive isoform characterized by rapid gating kinetics, undergoes significant transcriptional upregulation following nerve injury—a phenomenon largely absent in the mature nervous system under baseline conditions [Black et al., 1999; Waxman et al., 1994; Dib-Hajj et al., 1996, 1998; Kim et al., 2000]. This re-expression contributes to accelerated recovery cycles of sodium currents in nociceptive DRG neurons, thereby promoting high-frequency firing [Cummins et al., 1997]. Animal studies, encompassing models such as sciatic nerve transection and chronic constriction injury, reinforce Nav1.3's association with both inflammatory and neuropathic pain states [Black et al., 2004; Hains et al., 2003, 2004]. Despite compelling correlative data, some findings challenge the channel's functional indispensability; antisense-mediated knockdown and conditional knockout models failed to consistently attenuate pain behaviors [Hains et al., 2004; Nassar et al., 2006], suggesting compensatory mechanisms or spatial heterogeneity in expression may dilute its therapeutic relevance.

The Nav1.7 channel has garnered attention due to its pronounced expression in small-diameter DRG neurons and preferential localization to axonal growth cones—positions aligning it with pain transduction pathways [Toledo-Aral et al., 1997; Sangameswaran et al., 1997]. Its upregulation during inflammatory responses and the phenotypic consequences of Nav1.7 gene disruption underscore its dualistic involvement in pain physiology: gain-of-function mutations precipitate pathologies like primary erythromelalgia and paroxysmal extreme pain disorder via disrupted inactivation and enhanced persistent currents [Cummins et al., 2004; Fertleman et al., 2006], whereas complete channel ablation correlates with congenital insensitivity to pain [Cox et al., 2006].

These opposing phenotypes within human populations present a compelling argument for isoform-specific pharmacological targeting aimed at modulating, rather than abolishing, channel function.

Nav1.8, distinct from its TTX-sensitive counterparts, mediates a slow-gating, TTX-resistant current predominantly in small, nociceptive DRG neurons [Akopian et al., 1996]. Experimental interventions utilizing antisense oligonucleotides have demonstrated transient analgesic effects following suppression of Nav1.8 expression in neuropathic pain models [Gold et al., 2006; Lai et al., 2002], implicating its role in maintaining abnormal pain states. Yet, inconsistencies abound; upregulation is observed post-axotomy [Abdulla et al., 2002], while downregulation characterizes other neuropathic models [Decosterd et al., 2002; Sleeper et al., 2000], and knockout mice do not consistently exhibit attenuated pain phenotypes [Nassar et al., 2005]. A nuanced hypothesis posits that subcellular redistribution, particularly the peripheral translocation of Nav1.8 post-injury, might underlie its role in sustaining ectopic discharges, thereby offering an alternative framework for therapeutic modulation [Gold et al., 2006; Novakovic et al., 1998].Nav1.9, a lesser-explored TTX-resistant sodium channel isoform, exhibits a unique activation profile that aligns with resting membrane potentials, facilitating a persistent sodium current under physiological conditions [Porreca et al., 1999]. Notably enriched in small-diameter DRG neurons, its expression is paradoxically diminished following neural trauma [Sleeper et al., 2000]. This downregulation could recalibrate neuronal excitability by promoting membrane hyperpolarization, thereby enhancing the availability of TTX-sensitive channels—a compensatory mechanism not traditionally emphasized in pain models [Sleeper et al., 2000]. However, both silencing and gene ablation strategies targeting Nav1.9 have yielded inconclusive evidence regarding its necessity in neuropathic pain genesis [Porreca et al., 1999; Priest et al., 2005], suggesting the isoform may play a modulatory rather than indispensable role.Voltage-gated sodium channels are integral to the functional architecture of sensory neurons, orchestrating signal initiation and propagation through spatially regulated expression patterns. Synthesized in somata and trafficked along axons, their precise localization relies on scaffolding proteins such as ankyrin G, whose aberrant distribution post-injury may catalyze pathophysiological channel mislocalization [Bongenhielm et al., 2000]. Aberrant sodium influx via ectopically expressed VGSCs—particularly Nav1.7, Nav1.8, and Nav1.9—is increasingly recognized as a pivotal driver of peripheral-origin neuropathic pain [Bird et al., 2007]. Perturbations in mRNA expression patterns following injury reveal a nuanced reorganization: while Nav1.3 is prominently upregulated, aiding early-stage ectopic discharges, other isoforms such as Nav1.1, Nav1.2, Nav1.6, and Nav1.7 are concurrently suppressed [Kim et al., 2001]. Trigeminal nerve injury further corroborates this dynamic, with VGSCs aggregating at lesion sites during heightened neural excitability, implying a temporal and spatial regulatory mechanism [Davies et al., 2006]. The expression plasticity of these channels in diabetic and traumatic neuropathy models underscores their adaptive but potentially maladaptive role [Wood et al., 2004; Amir et al., 2006; Cummins et al., 2004; Craner et al., 2002].Functionally, Nav1.3 resurfaces prominently post-injury and in diabetic states, corresponding with electrophysiological signatures of rapid repriming sodium currents that perpetuate hyperexcitability [Cummins et al., 1997]. Similarly, Nav1.8 has emerged as a key player in nociception and thermosensation, contributing significantly to TTX-resistant currents in nociceptive DRG neurons. Genetic and pharmacological evidence robustly implicates Nav1.7 and Nav1.8 in chronic pain syndromes; for instance, siRNA-mediated knockdown of Nav1.7 and pathological gain-of-function mutations manifest in conditions like erythermalgia and paroxysmal extreme pain disorder through aberrant voltage gating and enhanced neuronal firing [Dib-Hajj et al., 2005; Fertleman et al., 2006]. Moreover, Nav1.8's role in thermal pain perception further validates its therapeutic relevance, especially in developing isoform-selective modulators [Momin et al., 2008].Despite existing sodium channel blockers being foundational in pain pharmacotherapy, their broad CNS effects and narrow therapeutic indices limit clinical utility. This underscores the urgency for novel analgesics with enhanced specificity. Nature-derived molecules, particularly conotoxins from marine cone snails, offer an exceptional model of selectivity, with mu-conotoxins demonstrating unparalleled isoform discrimination—selectively paralyzing skeletal muscle via Nav1.4 blockade while sparing CNS function [Wood et al., 2004]. These peptides, along with the clinically utilized ziconotide—a selective N-type calcium channel blocker—embody the translational promise of biologically inspired therapeutics [Wood et al., 2004; Momin et al., 2008]. Epidemiological data reveal neuropathic pain afflicts a substantial fraction of developed populations, with particularly high incidence among diabetic individuals in regions like New Zealand, where musculoskeletal and neuropathic conditions pose a public health crisis [Shipton, 2005; Bennett, 2006]. While anticonvulsants such as carbamazepine and gabapentin represent pharmacological mainstays, their efficacy is limited to subsets

of patients, reflecting the heterogeneity of pain mechanisms. Gabapentin's action via α2δ subunit inhibition of VGCCs has reinforced the role of calcium channels in pain transmission [Field et al., 2006]. Meanwhile, polypharmacological agents like amitriptyline and opioids exhibit broader mechanisms but are similarly constrained by side effect profiles [Haeseler et al., 2006; Wang et al., 2004]. These limitations fortify the imperative to innovate analgesics that achieve isoform selectivity, leveraging advancements in molecular pharmacology and natural product chemistry to transform the therapeutic landscape.

Emerging research has increasingly spotlighted the orphan G-protein coupled receptor GPR3 as a critical molecular interface at the nexus of neuroregeneration and pain modulation. GPR3 exhibits intrinsic activity by continuously stimulating cyclic AMP production within neurons, particularly within brain regions implicated in nociceptive processing and affective behavior regulation [Tanaka et al., 2007, 2009; Valverde et al., 2009]. This constitutive signaling facilitates neural repair mechanisms, notably enhancing axonal regrowth and neurite extension, which makes GPR3 a compelling candidate for therapeutic intervention in conditions such as stroke, neurodegenerative disorders, and traumatic CNS injuries [Tanaka et al., 2007]. In neuropathic contexts, functional knockout of GPR3 in mice yields a pronounced increase in thermal hypersensitivity following sciatic nerve ligation, while leaving responses to non-noxious mechanical stimuli unaffected. Baseline sensory responses, in both thermal and mechanical domains, remain unchanged between wild-type and GPR3-deficient animals, emphasizing that the receptor's influence is likely unmasked only during pathological conditions and does not disrupt foundational nociceptive pathways. This phenotype implies that GPR3 might specifically interface with thermal nociception pathways mediated by unmyelinated C-fibers, while sparing the Aβ-fiber-dependent mechanosensory circuits [Laird et al., 1993; Malmberg et al., 1998]. Such selective modulation echoes the roles observed in sigma-1 and MT2 melatonin receptors, which also demonstrate modality-specific involvement in pain states [Roh et al., 2008; Zurowski et al., 2008]. Given the preferential degeneration of C-fiber terminals in neuropathic conditions [Zimmermann, 2001], GPR3's capacity to promote axonal regeneration posits it as a neuroprotective element, potentially mediating adaptive remodeling post-injury. The absence of GPR3 may thus impair endogenous repair, exacerbating thermal nociceptive signaling and contributing to persistent pain. Notably, GPR3 expression within the habenula—a key limbic structure integrating pain and emotional states—suggests a dual functional architecture wherein the receptor modulates both the sensory intensity and affective appraisal of pain [Valverde et al., 2009; Benabid et al., 1989; Dai et al., 1993]. The habenula's response to nociceptive input and its capacity to mediate analgesia upon stimulation align with GPR3's purported role in emotional pain processing. Moreover, recent studies have uncovered a link between GPR3 signaling and the modulation of opioid efficacy. GPR3-deficient mice exhibit a blunted antinociceptive response to morphine without alterations in baseline nociceptive thresholds, suggesting a role for GPR3 in facilitating opioid receptor signaling or enhancing endogenous opioid tone [Poleshuck et al., 2010]. This positions GPR3 within a broader framework of a pro-opioid receptor network, wherein it may amplify or sustain the analgesic effects of opioids. Intriguingly, the lack of alteration in microglial and astrocytic activation in GPR3 knockout models post-injury further suggests that its modulatory effects operate independently of the neuroinflammatory cascades typically associated with chronic pain [DeLeo et al., 2001; Tanga et al., 2004].the Integrating Signaling Map of Neuropathic Pain Modulation via Non-Canonical Receptors was shown in Fig 4. Collectively, these insights underscore GPR3's multifaceted involvement in both the neurobiological and emotional spectrums of pain. By orchestrating cAMP-mediated regeneration and modulating nociceptive and opioid pathways, GPR3 emerges as a novel and highly strategic target for the treatment of neuropathic pain syndromes. Its unique anatomical distribution and modality-specific engagement offer a compelling rationale for its inclusion in future therapeutic strategies aimed at both repairing damaged neural circuits and alleviating the burden of chronic pain.

International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 16s,2025
https://theaspd.com/index.php



Figure 4: Integrated Signaling Map of Neuropathic Pain Modulation via Non-Canonical Receptors.

7.0 T-Type Calcium Channels: Emerging Modulators and Therapeutic Targets in Pain Perception

T-type calcium channels, long underappreciated in the context of nociceptive signaling, have recently emerged as potent modulators of pain perception, both in peripheral and central neural circuits. These low-voltage-activated channels, particularly the CaV3.2 isoform, have been identified as critical amplifiers of afferent sensory inputs, mediating heightened responses to somatic and visceral stimuli under pathological conditions. Their modulation appears to profoundly influence the pain threshold in experimental models, making them compelling targets for therapeutic intervention, especially where conventional analgesics fall short due to limited efficacy or debilitating side effects (Llinas et al., 1988; Perez-Reyes et al., 2003).

Compelling evidence from chronic constriction injury (CCI) models of neuropathy underscores the contribution of T-type channels to pain sensitization. Pharmacological blockade using selective antagonists such as (+)-ECN, mibefradil, and ethosuximide has been shown to significantly alleviate hyperalgesia and allodynia in affected rodents, particularly when administered locally, suggesting a dominant peripheral locus of action (Pathirathna et al., 2005; Dogrul et al., 2003). Mibefradil's lack of efficacy via intrathecal delivery further strengthens the notion that these channels exert their pro-nociceptive effects predominantly outside the spinal cord. Complementing these pharmacological insights, molecular approaches employing CaV3.2-specific antisense oligonucleotides have demonstrated prolonged reversal of pain hypersensitivity, supported by reductions in CaV3.2 mRNA and protein within dorsal root ganglia (DRG), but not spinal cord tissues (Bourinet et al., 2005). However, contrasting findings from CaV3.2 knockout models complicate the narrative. In particular, studies in genetically modified mice have failed to recapitulate the analgesic effects observed with acute pharmacological inhibition, potentially due to compensatory upregulation of alternative ion channels or interspecies differences in pain processing (Choi et al., 2007). Similarly, electrophysiological recordings have yielded inconsistent profiles, with some reports indicating selective depletion of T-type currents in specific DRG subpopulations post-injury, raising the possibility that differential cellular localization or channel isoform diversity may influence outcomes (Hogan et al., 2000; McCallum et al., 2003).

Beyond traumatic neuropathies, diabetic models such as the BB/W rat provide further insight into the role of T-type channels in pain dysregulation. These animals exhibit enhanced T-type and high-voltage-activated (HVA) calcium currents in DRG neurons, likely driven by aberrant G-protein signaling and potentially modulated by unidentified serum-derived factors (Hall et al., 1995, 1996; Ristic et al., 1998). This systemic modulation hints at a broader, endocrine-like regulation of neuronal excitability, underscoring the multifaceted role of T-type channels in neuropathic conditions.

At the cellular level, T-type channels are predominantly localized in small-diameter sensory neurons, which are generally associated with nociceptive functions. Their absence in large, non-nociceptive fibers suggests a degree of therapeutic specificity rarely seen in ion channel pharmacology. This preferential expression raises the prospect of developing channel blockers that selectively dampen pain without impairing other sensory modalities like proprioception or touch, a critical advantage over current therapies. Despite the compelling evidence of their presence in DRG somas, direct confirmation of T-type channel localization at peripheral terminals remains elusive, largely due to technical limitations imposed by the minute size of these structures. Nonetheless, antibody-based detection strategies targeting CaV3.2 may help bridge this gap.

Ultimately, the intricate interplay between T-type channel expression, sensory neuron subtype specificity, and pathological modulation in both traumatic and metabolic neuropathies affirms their relevance in pain research. Their role as molecular amplifiers of nociceptive input, coupled with the ability to discriminate between pain and non-pain modalities, marks them as highly strategic targets for next-generation analgesics. Future investigations must resolve current contradictions by elucidating cell-type specific responses and clarifying peripheral versus central mechanisms to fully harness the therapeutic potential of T-type calcium channel modulation.

Conclusion

The cannabinoid-based modulation of neuropathic pain marks a paradigm shift from blunt symptom suppression to targeted molecular recalibration. CB2 receptors act as immunoneural gatekeepers, transducing analgesic effects without the cognitive fog of central CB1 activation. FAAH and MAGL inhibitors amplify endogenous cannabinoid tone, weaving a biochemical safety net that dampens hyperexcitable pain circuits. Meanwhile, sigma-1 and imidazoline I2 receptors serve as master regulators of neuroplasticity, fine-tuning synaptic responses during chronic pain states. This constellation of targets invites a new era of smart analgesics multifunctional, side-effect-sparing, and rooted in the body's own endocannabinoid architecture. As we stand at the cusp of translational breakthroughs, these molecular strategies promise not just relief, but resilience rewriting the chronic pain narrative with scientific elegance and clinical promise.

REFERENCES

1. Abdulla FA, Smith PA. Changes in Na+ channel currents of rat dorsal root ganglion neurons following axotomy and axotomy-induced autotomy. J. Neurophysiol. 2002; 88: 2518-2529.
2. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 1993; 52:1049–1055.
3. Akin Takmaz S, Inan N, Gunal S et al., Ketamine combined with morphine for the management of cancer pain in a patient with meperidine tolerance and addiction. Agri 2005; 17:44-7
4. Amir R, Argoff CE, Bennett GJ, Cummins TR. The role of sodium channels in chronic inflammatory and neuropathic pain. Journal of Pain 2006;7:S1–29.
5. Armah BI, Hofferber E, Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung 1988; 38:1426–1434.
6. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol 2007;5:73–80.
7. Atwood BK, Mackie K. CB2, a cannabinoid receptor with an identity crisis. Br. J. Pharmacol 2010;160:467–479.
8. Aurilio C, Pota V, Pace MC, Passavanti MB, Barbarisi M. Ionic channels and neuropathic pain: physiopathology and applications. J Cell Physiol 2008;215:8—14.
9. Baderkhan, H, O Haller, A Wanhainen, M Björck, and K Mani. 2018. "Follow-up after Endovascular Aortic Aneurysm Repair Can Be Stratified Based on First Postoperative Imaging." British Journal of Surgery 105 (6): 709–18. https://doi.org/10.1002/bjs.10766.
10. Bernatoniene, Jurga, Arunas Sciupokas, Dalia Marija Kopustinskiene, and Kestutis Petrikonis. 2023. "Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain." Pharmaceutics 15 (7): 1799. https://doi.org/10.3390/pharmaceutics15071799.
11. Ben AR, Marouani N, Weinbroum AA. Dextromethorphan mitigates phantom pain in cancer amputees. Ann Surg Oncol 2003;10:268-74
12. Benabid AL, Jeaugey L. Cells of the rat lateral habenula respond to highthreshold somatosensory inputs. Neurosci. Lett. 1989;96:289:294.
13. Bennett AD, Everhart AW, Hulsebosch CE. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res 2000;859:72-82

14. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87–107.
15. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain
16. Bennett M. Neuropathic pain. Oxford: OUP; 2006.
17. Black JA, Cummins TR, Plumpton C. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J. Neurophysiol. 1999;82:2776-2785.
18. Black JA, Dib-Hajj S, Mcnabola K et al., Spinal sensory neurons express multiple sodium channel α-subunit mRNAs. Brain Res. Mol. Brain Res.1996; 43:117-131.
19. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004;108:237-247.
20. Boyce S, Wyatt A, Webb JK et al., Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-23
21. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, Rupniak NM. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611–23.
22. Chobanian, Harry R., Yan Guo, Ping Liu, Marc D. Chioda, Selena Fung, Thomas J. Lanza, Linda Chang, et al. 2014. "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain." ACS Medicinal Chemistry Letters 5 (6): 717–21. https://doi.org/10.1021/ml5001239.
23. Carlsson KC, Hoem NO, Moberg ER et al., Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36
24. Carlsson KC, Hoem NO, Moberg ER et al., Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36
25. Caudle RM, Perez FM, Del Valle-Pinero AY, Iadarola MJ. Spinal cord NR1 serine phosphorylation and NR2B subunit suppression following peripheral inflammation. Mol Pain 2005;1:25
26. Cendán CM, Pujalte JM, Portillo-Salido E, Baeyens JM. Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl) 2005a;182:485–493.
27. Cendán CM, Pujalte JM, Portillo-Salido E, Montoliu L, Baeyens JM. Formalininduced pain is reduced in sigma(1) receptor knockout mice. Eur J Pharmacol 2005b;511:73–74.
28. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al., Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006;148:102–113.
29. Chen SR, Eisenach JC, Mccaslin PP et al., Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology 2000;92:500-6
30. Chen SR, Pan HL. Antinociceptive effect of morphine, but not mu opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003;99:1409—1414.
31. Chen SR, Pan HL. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 2001;95:525—530.
32. Chen SR, Wess J, Pan HL. Functional activity of the M2 andM4 receptor subtypes in the spinal cord studied with muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther 2005; 313:765—770.
33. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, Fox CB. Separation of alpha-1 adrenergic and N-Methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 1991;34:3085–90
34. Chien CC, Pasternak GW. Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 1994;271:1583–1590.
35. Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 1995;190:137–139.
36. Childers WE Jr, Abou-Gharbia MA, Moyer JA et al., EAA-090: neuroprotectant competitive NMDA antagonist. Drugs Future 2002;27:633-8
37. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Annals of Neurology 2002;52:786–792.
38. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK et al., Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98:9371–9376.
39. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384:83–87.
40. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004;61:149–160.
41. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 2004b; 101:10821–10826.
42. Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 2004;24:8232-8236.
43. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 2007;131:243–257.
44. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 1997:17:3503-3514.
45. Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. Journal of Neuroscience 1997;17:3503–3514.
46. Cummins TR,Rush AM. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Expert Rev Neurotherapeutics 2007;7:1597—1612.

47. Dai JL, Ren ZJ, Fu ZM, Zhu YH, Xu SF. Electroacupuncture reversed the inhibition of intestinal peristalsis induced by intrathecal injection of morphine in rabbits. Chin. Med. J. 1993;106: 220-224.
48. Davies SL, Loescher AR, Clayton NM, Bountra C, Robinson PP, Boissonade FM. Changes in sodium channel expression following trigeminal nerve injury. Experimental Neurology 2006;202:207–216.
49. Davis AM, Inturrisi CE. Attenuation of hyperalgesia by LY235959, a competitive N-methyl-D-aspartate receptor antagonist. Brain Res 2001;894:150-3
50. Decosterd I, Ji RR, Abdi S, Tate S, Woolf CJ. The pattern of expression of the voltage-gated sodium channels Nav1.8 and Nav1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 2002;96:269-277.
51. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001;90:1-6.
52. Diaz A, Mayet S, Dickenson AH. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur. J. Pharmacol. 1997;333:9–15.
53. Dib-Hajj S, Black JA, Felts P, Waxman SG: Down-regulation of transcripts for Na channel α-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA 1996; 93:14950-14954.
54. Dib-Hajj SD, Binshtok A, Cummins TR, Jarvis M, Samad T, Zimmerman K. Voltagegated sodium channels in pain states: role in pathophysiology and targets for treatments. Brain Research Reviews 2009;60:65–83.
55. Dib-Hajj SD, Fjell J, Cummins TR et al., Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999;83:591-600.
56. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, et al. Gainof function mutation in Na(v)1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005;128:1847–1854.
57. Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc. Natl. Acad. Sci. USA 1998;95:8963-8968.
58. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur. J. Pain 2002; 6:51-60.
59. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987;26:1235–1238.
60. Dickenson AH. A cure for wind up,NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-9
61. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al., Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002;99: 10819–10824
62. Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porecca F. Reversal of experimental
63. Dogrul A, Ossipov MH, Lai J et al., Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 2000;292:115-8
64. Dohi T, Kitayama S, Morita K, Sato T, Arai S, Kumagai K et al., Inhibition of monoaine neurotransmitter transporters and central nervous system stimulation induced by synthetic local anesthetics and cocaine: a comparative review. Curr Med Chem CNS Agents 2002;2:295—315.
65. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 2000;4:5–15.
66. Fairbanks CA, Schreiber KL, Brewer KL et al., Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000;97:10584-9
67. Fairbanks CA, Stone LS, Wilcox GL. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol. Ther. 2009;123:224–238.
68. Fairbanks CA, Wilcox GL. Acute tolerance to spinally administered morphine comparesmechanisticallywith chronically inducedmorphine tolerance. J. Pharmacol. Exp. Ther. 1997;282:1408–1417.
69. Fairbanks CA, Wilcox GL. Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J. Pharmacol. Exp. Ther. 1999;290:403–412.
70. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767–774.
71. Fertleman CR, Baker MD, Parker KA.SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767-774.
72. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ et al., Identification of the alpha(2)-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proceedings of the National Academy of Sciences of the United States of America 2006;103:17537–42.
73. Field MJ, Li Z, Schwarz JB. Ca2þ channel alpha(2)-delta ligands for the treatment of neuropathic pain. Journal of Medicinal Chemistry 2007;50: 2569–75.
74. Field TA, Casey PJ. Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. Biochem 1997;J 321:561—571.
75. Fukui S, Komoda Y, Nosaka S. Clinical application of amantadine, an NMDA antagonist for neuropathic pain. J Anesth 2001;15:179-81
76. Fukui T, Dai Y, Iwata K, Kamo H, Yamanaka H, Obata K et al., Frequency-dependent ERK phosphorylation in spinal neurons by electric stimulation of the sciatic nerve and the role in electrophysiological activity. Mol Pain 2007;16:3–18.
77. Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 2001;15:29-58
78. Gerig, J.T. 2011. "Cross Relaxation in Liquid Methanol." Journal of Magnetic Resonance 210 (2): 171–76. https://doi.org/10.1016/j.jmr.2011.03.002.
79. Gilron I, Max MB, Lee G et al., Effects of the 2-amino-3-hydroxy-5- methyl-4-isoxazole-proprionic acid/kainite antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 2000;68:320-7